CA Patent

CA3125351A1 — Methods of modulating corticosteroid response

Assigned to Mallincrodt Pharmaceuticals Ireland Ltd · Expires 2020-07-23 · 6y expired

What this patent protects

The present disclosure is directed to methods of modulating corticosteroid responses in subjects in need thereof.

USPTO Abstract

The present disclosure is directed to methods of modulating corticosteroid responses in subjects in need thereof.

Drugs covered by this patent

Patent Metadata

Patent number
CA3125351A1
Jurisdiction
CA
Classification
—
Expires
2020-07-23
Drug substance claim
No
Drug product claim
No
Assignee
Mallincrodt Pharmaceuticals Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.